{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:04:20Z","timestamp":1789967060915,"version":"4.0.1"},"reference-count":24,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      Tegileridine, a novel G protein\u2010biassed \u03bc\u2010opioid receptor agonist, may offer effective postoperative analgesia with fewer opioid\u2010related adverse effects. This study evaluated its analgesic efficacy, safety and impact on surgical stress response\n                      <jats:italic>vs<\/jats:italic>\n                      . sufentanil for patient\u2010controlled intravenous analgesia (PCIA) in general surgery patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single\u2010centre, double\u2010blind, non\u2010inferiority trial, 120 adults scheduled for elective laparoscopic cholecystectomy, appendectomy or inguinal hernia repair were randomized 1:1 to 48\u2010h PCIA with tegileridine (5\u2009mg) or sufentanil (200\u2009\u03bcg), both with tropisetron 10\u2009mg. The primary outcome was 24\u2010h area under the curve (AUC) for resting visual analogue scale (VAS) pain scores, with a non\u2010inferiority margin of 10.6 points\u00b7h. Secondary outcomes included pain scores, PCIA usage, adverse events, recovery and plasma cortisol and interleukin\u20106 (IL\u20106).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All 120 patients completed the study. Mean 24\u2010h resting VAS\u2010AUC was 102.3\u2009\u00b1\u200925.6 points\u00b7h (tegileridine)\n                      <jats:italic>vs<\/jats:italic>\n                      . 105.8\u2009\u00b1\u200927.1 points\u00b7h (sufentanil). Upper 97.5% confidence limit for the difference was 9.8 points\u00b7h, below the 10.6 margin (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.001). Tegileridine significantly reduced postoperative nausea and vomiting (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.007) and accelerated gastrointestinal recovery (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.001). Postoperative cortisol and IL\u20106 elevations were significantly attenuated at 6 and 24\u2009h (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.001). No significant differences were observed for other adverse events or satisfaction.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tegileridine provides non\u2010inferior analgesia to sufentanil FOR PCIA after general surgery, with reduced PONV, faster gastrointestinal recovery and blunted stress response, supporting its potential role in enhanced recovery protocols.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>\n                      <jats:bold>Trial registration:<\/jats:bold>\n                      Chinese Clinical Trial Registry (ChiCTR2500114360).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70837","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:37:52Z","timestamp":1789965472000},"source":"Crossref","is-referenced-by-count":0,"title":["Tegileridine\n                    <i>vs<\/i>\n                    . sufentanil for postoperative analgesia in general surgery: A prospective, randomized, controlled, non\u2010inferiority trial."],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1839-537X","authenticated-orcid":false,"given":"Yingchuan","family":"Yuan","sequence":"first","affiliation":[{"name":"Department of Anesthesiology The Second Affiliated Hospital of Xinjiang Medical University  Urumqi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilin","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology The Second Affiliated Hospital of Xinjiang Medical University  Urumqi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunchao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology The Second Affiliated Hospital of Xinjiang Medical University  Urumqi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology The Second Affiliated Hospital of Xinjiang Medical University  Urumqi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology The Second Affiliated Hospital of Xinjiang Medical University  Urumqi China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,20]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2015.12.008"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.860019"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/aas.12651"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjon.2024.08.018"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjane.2024.844558"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643\u2010025\u201002933\u2010w"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/85.1.109"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/0148607113496117"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.100101"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010024\u201002033\u20104"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010020\u201001414\u20109"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000004758"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102477"},{"key":"e_1_2_9_15_1","unstructured":"National Medical Products Administration. Accessed 28 July 2026.https:\/\/english.nmpa.gov.cn\/"},{"key":"e_1_2_9_16_1","unstructured":"Tegileridine fumarate injection approved for marketing by China NMPA. Accessed 20 May 2026.https:\/\/english.nmpa.gov.cn\/2024-01\/31\/c_986554.htm"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S565369"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.70230"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aaz3140"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41422\u2010025\u201001191\u20108"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000004833"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2025.01.007"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/XCS.0000000000001919"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.2147\/JMDH.S572550"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1213\/01.ane.0000263034.96885.e1"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70837","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70837","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70837","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:38:00Z","timestamp":1789965480000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,20]]},"references-count":24,"alternative-id":["10.1002\/bcp.70837"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70837","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,20]]},"article-number":"bcp.70837"}}